Phospholamban R14del disease: The past, the present and the future

Elizabeth Vafiadaki*, Pieter C. Glijnis, Pieter A. Doevendans, Evangelia G. Kranias, Despina Sanoudou*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Arrhythmogenic cardiomyopathy affects significant number of patients worldwide and is characterized by life-threatening ventricular arrhythmias and sudden cardiac death. Mutations in multiple genes with diverse functions have been reported to date including phospholamban (PLN), a key regulator of sarcoplasmic reticulum (SR) Ca2+ homeostasis and cardiac contractility. The PLN-R14del variant in specific is recognized as the cause in an increasing number of patients worldwide, and extensive investigations have enabled rapid advances towards the delineation of PLN-R14del disease pathogenesis and discovery of an effective treatment. We provide a critical overview of current knowledge on PLN-R14del disease pathophysiology, including clinical, animal model, cellular and biochemical studies, as well as diverse therapeutic approaches that are being pursued. The milestones achieved in <20 years, since the discovery of the PLN R14del mutation (2006), serve as a paradigm of international scientific collaboration and patient involvement towards finding a cure.

Original languageEnglish
Article number1162205
JournalFrontiers in Cardiovascular Medicine
Volume10
DOIs
Publication statusPublished - 2023

Keywords

  • arrhythmias
  • cardiomyopathy
  • phospholamban
  • precision medicine
  • R14del mutation
  • therapy

Fingerprint

Dive into the research topics of 'Phospholamban R14del disease: The past, the present and the future'. Together they form a unique fingerprint.

Cite this